Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Free Cash Flow (2016 - 2025)

Ligand Pharmaceuticals' Free Cash Flow history spans 16 years, with the latest figure at $45.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 61.27% year-over-year to $45.9 million; the TTM value through Dec 2025 reached $20.5 million, down 7.15%, while the annual FY2025 figure was $49.4 million, 123.88% up from the prior year.
  • Free Cash Flow for Q4 2025 was $45.9 million at Ligand Pharmaceuticals, up from -$25.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $54.8 million in Q4 2022 and bottomed at -$38.0 million in Q3 2024.
  • The 5-year median for Free Cash Flow is $16.3 million (2021), against an average of $16.7 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 4779.07% in 2021 before it tumbled 630.2% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $32.6 million in 2021, then soared by 67.78% to $54.8 million in 2022, then crashed by 86.03% to $7.6 million in 2023, then surged by 272.27% to $28.5 million in 2024, then soared by 61.27% to $45.9 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Free Cash Flow are $45.9 million (Q4 2025), -$25.4 million (Q1 2025), and $28.5 million (Q4 2024).